QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
NASDAQ:NKTR

Nektar Therapeutics Stock Forecast, Price & News

$18.78
+0.54 (+2.96 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.57
Now: $18.78
$19.10
50-Day Range
$16.56
MA: $17.81
$19.21
52-Week Range
$13.63
Now: $18.78
$25.06
Volume2.22 million shs
Average Volume1.16 million shs
Market Capitalization$3.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics logo

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

331st out of 1,926 stocks

Pharmaceutical Preparations Industry

174th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300
Employees723
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$114.62 million
Book Value$7.99 per share

Profitability

Net Income$-440,670,000.00
Net Margins-269.05%

Miscellaneous

Market Cap$3.37 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$18.78
+0.54 (+2.96 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

How has Nektar Therapeutics' stock been impacted by Coronavirus?

Nektar Therapeutics' stock was trading at $16.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NKTR stock has increased by 14.0% and is now trading at $18.78.
View which stocks have been most impacted by COVID-19
.

Is Nektar Therapeutics a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Nektar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View analyst ratings for Nektar Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Nektar Therapeutics?

Wall Street analysts have given Nektar Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nektar Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among Nektar Therapeutics' employees.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Nektar Therapeutics
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.19. The biopharmaceutical company earned $30 million during the quarter, compared to analyst estimates of $22.82 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 30.74% and a negative net margin of 269.05%. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.56) EPS.
View Nektar Therapeutics' earnings history
.

What price target have analysts set for NKTR?

14 brokers have issued 1-year target prices for Nektar Therapeutics' shares. Their forecasts range from $18.00 to $80.00. On average, they anticipate Nektar Therapeutics' share price to reach $30.67 in the next year. This suggests a possible upside of 63.3% from the stock's current price.
View analysts' price targets for Nektar Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Nektar Therapeutics' key competitors?

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the following people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 67, Pay $1.19M)
  • Mr. Gilbert M. Labrucherie, Sr. VP, CFO & COO (Age 48, Pay $695.82k)
  • Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 54, Pay $470.79k)
  • Dr. Jonathan Zalevsky, Chief R&D Officer (Age 45, Pay $590.12k)
  • Mr. John P. Northcott, Sr. VP & Chief Commercial Officer (Age 42, Pay $269.56k)
  • Mr. Mark A. Wilson, Sr. VP, Gen. Counsel & Sec.
  • Ms. Jennifer Ruddock, Sr. VP of Strategy & Corp. Affairs
  • Dr. Mary Tagliaferri, Sr. VP & Exec. Clinical Fellow (Age 54)
  • Dr. Brian L. Kotzin, Sr. VP of Clinical Devel. & Head of Immunology Program (Age 71)
  • Dr. Kevin Brodbeck, Sr. VP of Manufacturing

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.75%), Candriam Luxembourg S.C.A. (0.17%), Frontier Capital Management Co. LLC (0.06%), Vista Wealth Management Group LLC (0.03%), Nisa Investment Advisors LLC (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Nektar Therapeutics stock include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, Mark Andrew Wilson, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends for Nektar Therapeutics
.

Which major investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Pacer Advisors Inc., Candriam Luxembourg S.C.A., State of Alaska Department of Revenue, and Mountain Capital Investment Advisors Inc. Company insiders that have sold Nektar Therapeutics company stock in the last year include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jonathan Zalevsky, Mark Andrew Wilson, R Scott Greer, and Robert Chess.
View insider buying and selling activity for Nektar Therapeutics
or view top insider-selling stocks.

Which major investors are buying Nektar Therapeutics stock?

NKTR stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Vista Wealth Management Group LLC, First Citizens Bank & Trust Co., Nisa Investment Advisors LLC, Penbrook Management LLC, and Exchange Traded Concepts LLC.
View insider buying and selling activity for Nektar Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $18.78.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $3.37 billion and generates $114.62 million in revenue each year. The biopharmaceutical company earns $-440,670,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis. Nektar Therapeutics employs 723 workers across the globe.

What is Nektar Therapeutics' official website?

The official website for Nektar Therapeutics is www.nektar.com.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.